目的:本研究旨在进行荟萃分析,以评估机器人辅助腹腔镜治疗中低位直肠癌患者的短期和长期治疗效果。
方法:采用综合搜索策略从PubMed检索相关文献,NCBI,Medline,和Springer数据库,从数据库开始到2023年8月。本系统综述的重点是对照研究,比较了机器人辅助(Rob)和传统腹腔镜(Lap)在中低位直肠癌的治疗效果。由两名独立研究人员(HMW和RKG)精心进行数据提取和文献综述。利用RevMan5.4软件对合成数据进行了严格的分析,在系统评价中坚持既定的方法标准。主要结果包括围手术期结果和肿瘤学结果。次要结果包括长期结果。
结果:共纳入11项研究,涉及2239例中低位直肠癌患者(3例RCT和8例NRCT);Rob组包括1111例,而Lap组包括1128例。Rob组术中出血较少(MD=-40.01,95%CI:-57.61~-22.42,P<0.00001),开放手术的转化率较低(OR=0.27,95%CI:0.09~0.82,P=0.02),收集的淋巴结数量较高(MD=1.97,95%CI:0.77至3.18,P=0.001),CRM阳性率较低(OR=0.46,95%CI:0.23~0.95,P=0.04)。此外,Rob组术后并发症发生率较低(OR=0.66,95%CI:0.53~0.82,P<0.0001),Clavien-Dindo分级≥3级并发症发生率较低(OR=0.60,95%CI:0.39~0.90,P=0.02).进一步的亚组分析显示吻合口漏发生率较低(OR=0.66,95%CI:0.45至0.97,P=0.04)。两组手术时间分析差异无统计学意义(P=0.42)。保护性造口的发生率(P=0.81),PRM(P=0.92),和DRM(P=0.23),排气时间(P=0.18),流质饮食时间(P=0.65),总住院时间(P=0.35),3年总生存率(P=0.67),3年无病生存率(P=0.42)。
结论:机器人辅助腹腔镜治疗中低位直肠癌的疗效良好,证明了疗效和安全性。与传统腹腔镜检查相比,患者术中出血减少,并发症发生率降低。值得注意的是,该方法实现了与传统腹腔镜手术相当的短期和长期治疗结果,因此有理由考虑其广泛的临床应用。
OBJECTIVE: This study aims to conduct a meta-analysis to evaluate the short-term and long-term therapeutic effects of robot-assisted laparoscopic treatment in patients with mid and low rectal cancer.
METHODS: A comprehensive search strategy was employed to retrieve relevant literature from PubMed, NCBI, Medline, and Springer databases, spanning the database inception until August 2023. The focus of this systematic review was on controlled studies that compared the treatment outcomes of robot-assisted (Rob) and conventional laparoscopy (Lap) in the context of mid and low rectal cancer. Data extraction and literature review were meticulously conducted by two independent researchers (HMW and RKG). The synthesized data underwent rigorous analysis utilizing RevMan 5.4 software, adhering to established methodological standards in systematic reviews. The primary outcomes encompass perioperative outcomes and oncological outcomes. Secondary outcomes include long-term outcomes.
RESULTS: A total of 11 studies involving 2239 patients with mid and low rectal cancer were included (3 RCTs and 8 NRCTs); the Rob group consisted of 1111 cases, while the Lap group included 1128 cases. The Rob group exhibited less intraoperative bleeding (MD = -40.01, 95% CI: -57.61 to -22.42, P < 0.00001), a lower conversion rate to open surgery (OR = 0.27, 95% CI: 0.09 to 0.82, P = 0.02), a higher number of harvested lymph nodes (MD = 1.97, 95% CI: 0.77 to 3.18, P = 0.001), and a lower CRM positive rate (OR = 0.46, 95% CI: 0.23 to 0.95, P = 0.04). Additionally, the Rob group had lower postoperative morbidity rate (OR = 0.66, 95% CI: 0.53 to 0.82, P < 0.0001) and a lower occurrence rate of complications with Clavien-Dindo grade ≥ 3 (OR = 0.60, 95% CI: 0.39 to 0.90, P = 0.02). Further subgroup analysis revealed a lower anastomotic leakage rate (OR = 0.66, 95% CI: 0.45 to 0.97, P = 0.04). No significant differences were observed between the two groups in the analysis of operation time (P = 0.42), occurrence rates of protective stoma (P = 0.81), PRM (P = 0.92), and DRM (P = 0.23), time to flatus (P = 0.18), time to liquid diet (P = 0.65), total hospital stay (P = 0.35), 3-year overall survival rate (P = 0.67), and 3-year disease-free survival rate (P = 0.42).
CONCLUSIONS: Robot-assisted laparoscopic treatment for mid and low rectal cancer yields favorable outcomes, demonstrating both efficacy and safety. In comparison to conventional laparoscopy, patients experience reduced intraoperative bleeding and a lower incidence of complications. Notably, the method achieves comparable short-term and long-term treatment results to those of conventional laparoscopic surgery, thus justifying its consideration for widespread clinical application.